HUYA Bioscience International and Quintiles, Inc. Announce Partnership for Phase I Development of New Cancer Therapy

SAN DIEGO & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--HUYA Bioscience International (HUYA), the leader in U.S.-China pharmaceutical co-development, and Quintiles, the only fully integrated biopharmaceutical services company offering clinical, commercial, consulting and capital solutions worldwide, today announced an agreement to co-develop a new cancer drug, HBI-8000, sourced in China by HUYA.

Back to news